SLC22A2 Antibody

What is SLC22A2/OCT2 and what is its significance in biomedical research?

SLC22A2 (Solute Carrier Family 22 Member 2), also known as OCT2 (Organic Cation Transporter 2), is a 62.5 kDa transmembrane protein composed of 555 amino acids in humans. It belongs to the solute carrier (SLC) protein superfamily, which includes over 300 members. This integral plasma membrane protein is encoded by the SLC22A2 gene mapped to chromosome 6q25.3 and contains 11 exons . The protein is primarily expressed in the kidney, specifically at the basolateral membrane of renal proximal tubules, with additional expression in the placenta, brain, skin, lung, spleen, and small intestine .

SLC22A2 functions as a polyspecific transporter mediating the electrogenic transport of small organic cations . Its importance in research lies in its role in drug transport, disposition, and potential involvement in drug-drug interactions. Understanding SLC22A2 expression patterns and regulatory mechanisms is crucial for pharmacology, toxicology, and nephrology research.

What species reactivity is available for commercially produced SLC22A2 antibodies?

SLC22A2 antibodies are available with reactivity against multiple species, allowing for comparative studies across experimental models. Based on the search results, researchers can obtain antibodies specific for:

It's important to note that some antibodies have specific reactivity limitations. For example, the ACT-020 antibody is designed specifically for rat and mouse samples and will not recognize human OCT2 . Always verify cross-reactivity before conducting cross-species studies.

What common applications are SLC22A2 antibodies validated for?

SLC22A2 antibodies have been validated for multiple experimental applications, with varying degrees of optimization for different techniques:

For kidney studies specifically, multiple antibodies have shown strong and specific staining of proximal tubules, consistent with the known expression pattern of SLC22A2 .

How should SLC22A2 antibodies be stored and handled to maintain optimal activity?

Proper storage and handling of SLC22A2 antibodies are crucial for maintaining their specificity and sensitivity. Based on manufacturer recommendations:

For lyophilized or concentrated antibodies:

• Store unopened at -20°C to -70°C for up to 12 months from the date of receipt

• After reconstitution, store at 2-8°C for up to 1 month under sterile conditions

• For longer storage after reconstitution, aliquot and store at -20°C to -70°C for up to 6 months under sterile conditions

• Avoid repeated freeze-thaw cycles as these can significantly reduce antibody activity

For working dilutions:

• Prepare fresh working dilutions on the day of the experiment whenever possible

• Optimal dilutions should be determined empirically for each application and experimental system

• Include appropriate controls to verify antibody performance in each experiment

How do I select the optimal SLC22A2 antibody for kidney research?

Selecting the appropriate SLC22A2 antibody for kidney research requires consideration of several factors:

Epitope location considerations:

• For studying membrane topology: Choose antibodies targeting extracellular domains for non-permeabilized experiments or intracellular epitopes for studying internal domains after permeabilization

• The ACT-020 antibody targets amino acid residues 321-334 of mouse SLC22A2, corresponding to the intracellular third loop of the protein

Validation in kidney tissue:

• Prioritize antibodies with demonstrated specificity in kidney tissues

• MAB6547 has been validated in human kidney using both chromogenic IHC and fluorescent methods

• ACT-020 shows specific staining in mouse kidney proximal tubules that can be blocked with the corresponding peptide

Detection method compatibility:

• For brightfield microscopy: HRP-DAB detection systems work well with several SLC22A2 antibodies

• For fluorescence: Antibodies compatible with Alexa Fluor conjugates have been validated

• For multiplex studies: Consider host species compatibility with other primary antibodies

Technical validation approach:

• Perform peptide blocking controls using specific blocking peptides like BLP-CT020

• Include positive control tissues (kidney) and negative control tissues (tissues not expressing SLC22A2)

• Compare staining patterns with published literature and gene expression databases

What are the optimal antigen retrieval methods for SLC22A2 detection in fixed tissues?

Antigen retrieval is critical for successful SLC22A2 detection in fixed tissues, as fixation can mask epitopes. Based on the search results:

Heat-induced epitope retrieval (HIER):

• Citrate buffer (pH 6.0) has been successfully used for SLC22A2 detection in formalin-fixed paraffin-embedded (FFPE) mouse kidney sections

• For human kidney tissues, Dewax and HIER Buffer H (pH 9) has been effectively used with the MAB6547 antibody

Protocol parameters:

• Temperature: 37°C incubation for 4 minutes has been reported with MAB6547 in human kidney

• Duration: Optimal times vary by tissue preparation method and antibody

• Equipment: Both manual methods and automated systems (like PreTreatment Module/PT Module) have been used successfully

Tissue-specific considerations:

• Kidney tissues generally require moderate retrieval conditions

• Brain tissues may require optimization due to lipid content

• Always include a positive control tissue with known SLC22A2 expression to confirm retrieval efficacy

Frozen vs. FFPE considerations:

• Frozen sections may require milder or no retrieval

• FFPE sections typically require more aggressive retrieval methods

How can I validate SLC22A2 antibody specificity in my experimental system?

Validating antibody specificity is crucial for generating reliable data. For SLC22A2 antibodies, consider these validation strategies:

Peptide competition/blocking:

• Pre-incubate the antibody with the immunizing peptide (e.g., SLC22A2 Blocking Peptide BLP-CT020)

• Compare staining between blocked and unblocked antibody samples

• Specific staining should be significantly reduced or eliminated in the presence of the blocking peptide

Genetic models:

• Use SLC22A2 knockout tissues/cells as negative controls

• Overexpression systems (e.g., transfected cell lines) can serve as positive controls

• HEK293 cells transfected with human SLC22A2 have been used successfully for antibody validation

Orthogonal validation:

• Compare protein detection with mRNA expression data

• Use multiple antibodies targeting different epitopes of SLC22A2

• The Human Protein Atlas employs this approach for antibody validation

Western blot validation:

• Confirm the detection of a band at the expected molecular weight (~62.5 kDa for human SLC22A2)

• Mouse and rat kidney lysates have been used as positive controls

• Brain lysates may show different expression patterns or isoforms

What are the key considerations when using SLC22A2 antibodies in transporter function studies?

When investigating SLC22A2 transporter function in relation to protein expression:

Correlation of expression with function:

• Ensure that antibody detection accurately reflects functional protein

• Membrane localization is critical for transporter function

• Use subcellular fractionation techniques to distinguish between total and membrane-localized SLC22A2

Trafficking studies:

• Consider fixation methods that preserve membrane structures

• Use co-localization with membrane markers to confirm proper localization

• For internalization studies, surface biotinylation with antibody detection can track protein movement

Functional validation approaches:

• Complement antibody studies with functional transport assays

• Correlate protein expression levels with transport capacity

• Consider the impact of post-translational modifications on both detection and function

Technical considerations:

• For flow cytometry in functional studies, protocols like "Staining Membrane-associated Proteins" have been validated

• Use non-permeabilized conditions to specifically detect surface-expressed transporters

• For cells expressing both endogenous and exogenous SLC22A2, epitope-tagged constructs can help distinguish populations

What protocols are recommended for immunohistochemical detection of SLC22A2 in kidney tissues?

For optimal immunohistochemical detection of SLC22A2 in kidney tissues:

FFPE tissue protocol:

• Section preparation: Cut paraffin sections at 4-6 μm thickness

• Deparaffinization: Use standard xylene and graded ethanol series

• Antigen retrieval: Heat-induced epitope retrieval with citrate buffer (pH 6.0) or pH 9 buffer

• Blocking: Block endogenous peroxidase activity and non-specific binding

• Primary antibody incubation:

  • MAB6547: 25 μg/mL overnight at 4°C or 20 μg/mL at 37°C for 4 minutes

  • ACT-020: 1:100 dilution (for mouse kidney)

• Detection system:

  • Chromogenic: Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (for MAB6547)

  • Fluorescent: Alexa Fluor 647 secondary antibody at 1:200 dilution (for MAB6547)

  • Alexa Fluor secondary antibodies for ACT-020

• Counterstaining: Hematoxylin for brightfield or DAPI for fluorescence

Frozen tissue protocol:

• Tissue preparation: Perfusion fixation followed by cryoprotection

• Sectioning: Cut 10-20 μm sections using a cryostat

• Fixation: Post-fixation with 4% paraformaldehyde if needed

• Blocking: Block with appropriate serum or BSA solution

• Primary antibody incubation: ACT-020 at 1:200 dilution

• Detection: Appropriate fluorophore-conjugated secondary antibody

• Counterstaining: DAPI for nuclear visualization

How can SLC22A2 expression be quantitatively assessed using antibody-based methods?

Quantitative assessment of SLC22A2 expression requires rigorous methodology:

Western blot quantification:

• Sample preparation: Use standardized protein extraction protocols for renal tissues or cells

• Loading controls: Include housekeeping proteins and/or total protein staining methods

• Standard curves: Consider including recombinant SLC22A2 standards for absolute quantification

• Densitometry: Use calibrated software tools for band intensity measurement

• Normalization: Express SLC22A2 levels relative to loading controls

Flow cytometry quantification:

• Single cell preparations: Optimize tissue dissociation protocols to maintain epitope integrity

• Antibody titration: Determine optimal concentration for specific signal-to-noise ratio

• Calibration beads: Use fluorescence calibration beads to convert to absolute units

• Controls: Include unstained, isotype, and single-stained controls

• Analysis: Report median fluorescence intensity (MFI) or molecules of equivalent soluble fluorochrome (MESF)

Immunohistochemistry quantification:

• Image acquisition: Use standardized exposure settings and microscopy parameters

• Region selection: Define regions of interest (ROIs) containing proximal tubules

• Background correction: Subtract non-specific staining signal

• Reference standards: Include calibration slides with known expression levels when possible

• Analysis software: Utilize image analysis platforms with validated algorithms for membrane protein quantification

What troubleshooting approaches are recommended for inconsistent SLC22A2 antibody results?

When facing inconsistent results with SLC22A2 antibodies, consider these troubleshooting approaches:

High background issues:

• Increase blocking time/concentration

• Optimize antibody concentration through careful titration

• Ensure adequate washing steps (duration and buffer composition)

• For fluorescence applications, include an autofluorescence quenching step

Weak or absent signal:

• Verify tissue expression using positive control samples (kidney)

• Optimize antigen retrieval conditions (buffer pH, time, temperature)

• Extend primary antibody incubation time or increase concentration

• Ensure antibody storage conditions are appropriate

• Check compatibility between primary and secondary antibodies

Non-specific binding:

• Perform peptide competition controls to identify specific vs. non-specific signals

• Use knockout or knockdown samples as negative controls

• Try alternative blocking reagents (normal serum, BSA, casein)

• Consider using more highly purified antibody formulations

Variability between replicates:

• Standardize tissue collection and fixation protocols

• Control fixation time precisely

• Batch process samples when possible

• Develop detailed SOPs for critical steps in the protocol

• Consider automated staining platforms for improved consistency

How can SLC22A2 antibodies be effectively used in multiple labeling experiments?

For multiple labeling of SLC22A2 with other proteins:

Antibody selection considerations:

• Choose primary antibodies from different host species to avoid cross-reactivity

• If using same-species antibodies, consider directly conjugated antibodies or sequential staining protocols

• Verify that epitope accessibility is not affected by multiple labeling procedures

Fluorophore selection strategies:

• Select fluorophores with minimal spectral overlap

• For kidney tissues with high autofluorescence, use far-red fluorophores like Alexa Fluor 647

• Consider signal intensity balancing based on relative protein abundance

Protocol optimization for co-localization studies:

• Fixation: Select fixatives that preserve all target antigens

• Antigen retrieval: Use conditions compatible with all target proteins

• Blocking: Block with serum from all secondary antibody host species

• Sequential or simultaneous incubation:

  • Simultaneous: Mix compatible primary antibodies

  • Sequential: Complete first antibody staining with direct labeling, followed by second antibody

• Controls: Include single-stained controls for spillover compensation

• Analysis: Use appropriate co-localization algorithms and statistics

Application example:
Co-staining SLC22A2 with proximal tubule markers (e.g., megalin) or other transporters (e.g., OATs) can provide important insights into transporter localization and potential functional relationships in the kidney.

How can SLC22A2 antibodies be used to study drug transport mechanisms?

SLC22A2 antibodies enable several approaches to investigate drug transport mechanisms:

Expression-function correlation studies:

• Quantify SLC22A2 expression levels using antibodies in different experimental models

• Correlate expression with transport activity of substrate drugs

• Investigate how genetic variants or regulatory factors affect both expression and function

Localization in drug disposition tissues:

• Map SLC22A2 distribution in key drug handling tissues (kidney, placenta)

• Identify cell-specific expression patterns relevant to drug disposition

• Determine subcellular localization in polarized cells

Regulation mechanisms:

• Study how drug exposures affect SLC22A2 expression and localization

• Investigate trafficking dynamics under various physiological and pathological conditions

• Examine post-translational modifications using modification-specific antibodies

Translational applications:

• Compare expression patterns between experimental animal models and human tissues

• Investigate expression changes in disease states that might affect drug handling

• Assess potential drug-drug interactions at the transporter level

What are the considerations when using SLC22A2 antibodies in disease-related research?

When applying SLC22A2 antibodies to disease-related research:

Cancer research considerations:

• Recent studies have investigated SLC22A2 expression in renal cell carcinoma in relation to oxaliplatin sensitivity

• Compare expression between tumor and adjacent normal tissue

• Correlate expression with clinical parameters and treatment response

Kidney disease applications:

• Assess changes in SLC22A2 expression during acute kidney injury or chronic kidney disease

• Investigate how altered expression affects drug clearance and potential toxicity

• Compare expression patterns across different nephron segments in disease states

Neurodegenerative disease research:

• Given SLC22A2 expression in the brain, particularly in the cerebral cortex and subcortical nuclei , antibodies can help map expression in relation to neurological disorders

• For brain tissue studies, optimize protocols specifically for neuronal detection

Experimental design recommendations:

• Include appropriate disease and control samples

• Consider both qualitative (localization changes) and quantitative (expression level) assessments

• Correlate protein expression with functional assays and clinical parameters where possible